Cabergoline


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Adjunct to levodopa treatment in Parkinson's disease, Monotherapy in Parkinson's disease
Adult: Initially, 1 mg daily, gradually increase by 0.5-1 mg at 1 or 2 wk interval until optimal response. Recommended dose: 2-3 mg daily.

Oral
Inhibition of physiological lactation
Adult: 1 mg as a single dose on the 1st day postpartum.

Oral
Hyperprolactinaemia-associated disorders
Adult: Initially, 0.5 mg wkly, increase gradually, preferably in increments of 0.5 mg wkly at mthly intervals until optimal response. Wkly dose may be given in 1 or 2 divided doses on separate days. Usual dose: 1 mg wkly (range: 0.25-2 mg, up to 4.5 mg wkly).

Oral
Suppression of lactation
Adult: 250 mcg 12 hrly for 2 days.
Cách dùng
Should be taken with food.
Chống chỉ định
Uncontrolled HTN; history of pulmonary, pericardial, and retroperitoneal fibrotic disorders; cardiac valvular disorders. Toxaemia of pregnancy, history of puerperal psychosis. Concomitant use w/ dopamine antagonists.
Thận trọng
Patients w/ severe CV disease, Raynaud’s syndrome, peptic ulcer, GI bleeding. Renal or hepatic impairment. Pregnancy and lactation.
Phản ứng phụ
Abdominal pain, angina, breast pain, confusion, constipation, depression, dyspepsia, epigastric pain, gastritis, hallucinations, headache, nausea, syncope, postural hypotension, somnolence, allergic skin reactions, alopecia, cardiac valvulopathy, constrictive pericarditis, drowsiness, dyskinesia, erythromelalgia, hypersexuality, hypotension, increased libido, leg cramps, pericardial effusion, pathological gambling, peripheral oedema, pleural effusion/fibrosis, pleuritis, pulmonary/retroperitoneal fibrosis. Rarely, digital vasospasm, epistaxis, hot flushes, muscle weakness, palpitation, paraesthesia, transient hemianopia, vomiting.
Thông tin tư vấn bệnh nhân
May impair ability to drive or operate machinery.
MonitoringParameters
Monitor BP; serum prolactin level (mthly until normalised); echocardiogram (at baseline and 6-12 mthly); ESR, chest X-ray, and serum creatinine level; signs and symptoms of pleuropulmonary disease, ureteral/abdominal vascular obstruction. Perform pregnancy test prior to initiation of therapy.
Quá liều
Symptoms: Nausea, vomiting, gastric complaints, postural hypotension, confusion/psychosis or hallucinations. Management: Supportive treatment. Admin of dopamine antagonist may be advisable.
Tương tác
Increased risk of orthostatic hypotension when used w/ antihypertensives. Additive therapeutic effect w/ levodopa. Increased systemic bioavailability w/ macrolide antibiotics (e.g. erythromycin).
Potentially Fatal: Diminished therapeutic effect w/ dopamine antagonist (e.g. phenothiazines, butyrophenones, thioxanthines, metoclopramide).
Tác dụng
Description: Cabergoline is a long-acting dopamine D2-agonist. It inhibits prolactin secretion through hypothalamic inhibitory control exerted through the release of dopamine.
Duration: Prolactin-lowering effect: 14 days.
Pharmacokinetics:
Absorption: Absorbed from the GI tract. Time to peak plasma concentration: 2-3 hr.
Distribution: Extensively distributed throughout the body. Crosses the placenta and enters breast milk. Plasma protein binding: 40-42%.
Metabolism: Metabolised in the liver via hydrolysis of the acylurea bond (w/ minimal CYP involvement). Undergoes first-pass metabolism.
Excretion: Via faeces (approx 60%) and urine (approx 22%; <4% as unchanged drug). Elimination half-life: 63-69 hr.
Đặc tính

Chemical Structure Image
Cabergoline

Source: National Center for Biotechnology Information. PubChem Database. Cabergoline, CID=54746, https://pubchem.ncbi.nlm.nih.gov/compound/Cabergoline (accessed on Jan. 21, 2020)

Bảo quản
Store between 20-25°C.
Phân loại ATC
N04BC06 - cabergoline ; Belongs to the class of dopamine agonist. Used in the management of Parkinson's disease.
G02CB03 - cabergoline ; Belongs to the class of prolactine inhibitors. Used to suppress lactation.
References
Anon. Cabergoline. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/10/2016.

Buckingham R (ed). Cabergoline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/10/2016.

Cabergoline Tablet (Greenstone LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/10/2016.

Joint Formulary Committee. Cabergoline. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/10/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Cabergoline. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 03/10/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Cabergoline từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in